학술논문
Who 'nose', is it the angiotensin receptor neprilysin inhibitor?: a case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan
CASE SERIES: Heart failure
CASE SERIES: Heart failure
Document Type
Academic Journal
Author
Source
EHJ Case Reports. December 2021, Vol. 5 Issue 12
Subject
Language
English
ISSN
2514-2119
Abstract
Introduction Sacubitril/valsartan is the first agent to be approved in a new class of medications called angiotensin receptor neprilysin inhibitor (ARNi). The medication is efficacious in reducing mortality and morbidity [...]
Background Sacubitril/valsartan is approved for the treatment of chronic heart failure with reduced left ventricular ejection fraction of Case summary Three patients aged 58-73 years-old presented with pruritus at the nasal septum post-initiation of sacubitril/valsartan. The pruritus did not subside despite the use of anti-histamines. Within 3-6 months, all individuals discontinued sacubitril/valsartan with complete resolution of their nasal pruritus. Discussion Many physicians may not aware of this unusual but reversible adverse effect of sacubitril/valsartan. Despite the positive prognostic value of sacubitril/valsartan, the constant nasal pruritus had impacted the quality of life of our patients, leading them to discontinue sacubitril/valsartan permanently. Keywords Sacubitril/valsartan * Entresto * ARNi * Nasal pruritus * Allergy * Case series ESC Curriculum 6.2 Heart failure with reduced ejection fraction * 9.9 Cardiological consultations
Background Sacubitril/valsartan is approved for the treatment of chronic heart failure with reduced left ventricular ejection fraction of Case summary Three patients aged 58-73 years-old presented with pruritus at the nasal septum post-initiation of sacubitril/valsartan. The pruritus did not subside despite the use of anti-histamines. Within 3-6 months, all individuals discontinued sacubitril/valsartan with complete resolution of their nasal pruritus. Discussion Many physicians may not aware of this unusual but reversible adverse effect of sacubitril/valsartan. Despite the positive prognostic value of sacubitril/valsartan, the constant nasal pruritus had impacted the quality of life of our patients, leading them to discontinue sacubitril/valsartan permanently. Keywords Sacubitril/valsartan * Entresto * ARNi * Nasal pruritus * Allergy * Case series ESC Curriculum 6.2 Heart failure with reduced ejection fraction * 9.9 Cardiological consultations